News & Videos - ANTHERA PHARMACEUTICALS INC.

...

...

...

...

Johnson & Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation PR Newswire SAN DIEGO, Feb. 18, 2017 SAN DIEGO , Feb. 18, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential claims against Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation, as detailed below: Clovis Oncology, Inc. Johnson & Weaver, LLP...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

Lifshitz & Miller LLP Announces Investigation of Anthera Pharmaceuticals, Inc., Arctic Cat Inc., Banc of California, Inc., Dollar General Corporation, MoneyGram International, Inc., QUALCOMM Incorporated, Stonegate Mortgage Corporation and Unilife Corporation PR Newswire NEW YORK, Feb. 3, 2017 NEW YORK , Feb. 3, 2017 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (ANTH) Lifshitz & Miller announces investigation on behalf of ANTH investors concerning the development of CHABLIS-SC1 and liprotamase...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anthera Pharmaceuticals, Inc. (ANTH) PR Newswire NEW YORK, Jan. 17, 2016 NEW YORK , Jan. 17, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the "Company") (NASDAQ: ANTH). Such investors are encouraged to obtain additional information and assist the investigation by visiting the...

Sollpura narrowly missed the primary endpoint for change in the Coefficient of Fat Absorption (CFA) non-inferiority margin Sollpura demonstrated non-inferiority in the per protocol CFA analysis Sollpura demonstrated non-inferiority in Coefficient of Nitrogen Absorption (CNA) analyses Anthera will initiate a new study to demonstrate the efficacy of Sollpura by addressing the scientific findings from the SOLUTION study; anticipates BLA Filing 1Q’18 HAYWARD, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE)...

HAYWARD, Calif., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data Monitoring Committee (DMC) completed its pre-planned safety review of the SIMPLICITY clinical study of Sollpura supplied as a powder for oral solution in an initial cohort of cystic fibrosis patients seven years of age and older with exocrine pancreatic insufficiency. The DMC was in unanimous agreement “that there are no safety concerns and that the study can move...

J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman of the Board but will remain as Director HAYWARD, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Today the Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) Board of Directors announced J. Craig Thompson has been promoted to Chief Executive Officer. Mr. Thompson has also been appointed to serve as a member of...

Lower proteinuria in blisibimod versus placebo treated patients Changes in circulating B-cells and serum immunoglobulins consistent with BAFF inhibition HAYWARD, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced positive trends from the Week 48 analysis of the Phase 2 BRIGHT-SC proof-of-concept study in 57 patients with IgA nephropathy. The effects of blisibimod versus placebo were assessed through at least the 48 week time point in all...

Assessing next steps for blisibimod for the treatment of Systemic Lupus Erythematosus Continuing to explore blisibimod as treatment for IgA nephropathy – Phase 2 data in December Sollpura TM SOLUTION phase 3 study in exocrine pancreatic insufficiency on track for topline data in December HAYWARD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus...

Blisibimod topline data from the Phase 3 CHABLIS-SC1 Study in severe lupus patients is imminent Data and Safety Monitoring Board recommendation to continue SOLUTION study with Sollpura™ FDA Type C meeting in September validated basis for BLA filing and manufacturing approach for Sollpura™ Closing of initial $17 million registered direct offering Appointed William Shanahan Jr., M.D., J.D. as Chief Medical Officer HAYWARD, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc....

HAYWARD, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that an abstract of the interim data from the Phase 2 BRIGHT-SC clinical study evaluating the treatment effect of blisibimod in patients with biopsy-proven IgA Nephropathy (IgAN) has been accepted as a late-breaking poster presentation at the 2016 American Society of Nephrology’s Kidney Week Annual Meeting. “These data provide hope to patients with IgAN, for whom no approved therapy...